Therapeutic drug monitoring of atypical antipsychotic drugs

Open access


Schizophrenia is a severe psychiatric disorder often associated with cognitive impairment and affective, mainly depressive, symptoms. Antipsychotic medication is the primary intervention for stabilization of acute psychotic episodes and prevention of recurrences and relapses in patients with schizophrenia. Typical antipsychotics, the older class of antipsychotic agents, are currently used much less frequently than newer atypical antipsychotics. Therapeutic drug monitoring (TDM) of antipsychotic drugs is the specific method of clinical pharmacology, which involves measurement of drug serum concentrations followed by interpretation and good cooperation with the clinician. TDM is a powerful tool that allows tailor-made treatment for the specific needs of individual patients. It can help in monitoring adherence, dose adjustment, minimizing the risk of toxicity and in cost-effectiveness in the treatment of psychiatric disorders. The review provides complex knowledge indispensable to clinical pharmacologists, pharmacists and clinicians for interpretation of TDM results.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. M. Grundmann and I. Kacirova Significance of TDM phenotyping and genotyping for the correct drug dosage Cas. Lek. Ces. 149 (2010) 482-487.

  • 2. M. Grundmann I. Kacirova and R. Urinovska Therapeutic monitoring of psychoactive drugs - antidepressants: A review Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. (2013) in press; DOI: 10.5507/bp.2013.020.

  • 3. I. Kacirova M. Grundmann and R. Urinovska General principles of therapeutic monitoring of psychoactive drugs Klin. Farmakol. Farm. 26 (2012) 131-134.

  • 4. C. Hiemke and M. Shams Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry Curr. Drug Del. 10 (2013) 46-53.

  • 5. M. R. Muscatello A. Bruno G. Pandolfo U. Micò S. Settineri and R. Zoccali Emerging treatments in the management of schizophrenia - focus on sertindole Drug Des. Devel. Ther. 4 (2010) 187-201; DOI: 10.2147/DDDT.S6591.

  • 6. J. M. Kane and C. U. Correll Past and present progress in the pharmacologic treatment of schizophrenia J. Clin. Psychiatry 71 (2010) 1115-1124; DOI: 10.4088/JCP.10r06264yel

  • 7. J. W. Newcomer Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 19 (Suppl. 1) (2005) 1-93.

  • 8. N. Herrmann and K. L. Lanctot Do atypical antipsychotics cause stroke? CNS Drugs 19 (2005) 91-103.

  • 9. B. Luft and D. Taylor A review of atypical antipsychotic drugs versus conventional medication in schizophrenia Expert Opin. Pharmacother. 7 (2006) 1739-1748.

  • 10. J. C. Huffman and J. E. Alpert An approach to the psychopharmacologic care of patients: antidepressants antipsychotics anxiolytics mood stabilizers and natural remedies Med. Clin. North Am. 94 (2010) 1141-1160; DOI: 10.1016/j.mcna.2010.08.009.

  • 11. C. Hiemke A. Dragicevic G. Gründer S. Hättter J. Sachse I. Vernaleken and M. J. Müller Therapeutic monitoring of new antipsychotic drugs Ther. Drug Monit. 26 (2004) 156-160.

  • 12. L. Farde A. L. Nordström F. A. Wiesel S. Pauli C. Halldin and G. Sedvall Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects Arch. Gen. Psychiatry 49 (1992) 538-544.

  • 13. S. Nyberg A. L. Nordström C. Halldin and L. Farde Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man Int. Clin. Psychopharmacol. 10 (Suppl. 3) (1995) 81-85.

  • 14. P. J. Perry Therapeutic drug monitoring of atypical antipsychotics. Is it of potential clinical value? CNS Drugs 13 (2000) 167-171.

  • 15. M. C. Mauri L. S. Volonteri A. Colasanti A. Fiorentini I. F. de Gaspari and S. R. Bareggi Clinical pharmacokinetics of atypical antipsychotics. A critical review of the relationship between plasma concentrations and clinical response Clin. Phamacokinet. 46 (2007) 359-388.

  • 16. L. Urichuk T. I. Prior S. Dursun and G. Baker Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions Curr. Drug Metab. 9 (2008) 410-418.

  • 17. E. Spina and J. de Leon Metabolic drug interactions with newer antipsychotics: A comparative review Basic Clin. Pharmacol. 100 (2007) 4-22.

  • 18. R. C. Dorey S. H. Preskorn and P. K. Widener Results compared for tricyclic antidepressants as assayed by liquid chromatography and enzyme immunoassay Clin. Chem. 34 (1988) 2348-2351.

  • 19. F. Saint-Marcoux F. L. Sauvage and P. Marquet Current role of LC-MS in therapeutic drug monitoring Anal. Bioanal. Chem. 388 (2007) 1327-1349.

  • 20. D. J. Brunswick B. Needelman and J. Mendels Specific radioimmunoassay of amitriptyline and nortriptyline J. Clin. Pharmacol. 7 (1979) 343-348.

  • 21. C. Fernandes E. Hoeck P. Sandra and F. M. Lancas Determination of fluoxetine in plasma by gas chromatography-mass spectrometry using stir bar sorptive extraction Anal. Chim. Acta 614 (2008) 201-207; DOI: 10.1016/j.aca.2008.03.036.

  • 22. C. B. Eap G. Bouchoux M. Amey N. Cochard L. Savary and P. Baumann Simultaneous determination of human plasma levels of citalopram paroxetine sertraline and their metabolites by gas chromatography-mass spectrometry J. Chromatogr. Sci. 36 (1998) 365-371.

  • 23. R. Urinovska H. Brozmanova P. Sistik P. Silhan I. Kacirova K. Lemr and M. Grundmann Liquid chromatography-tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum J. Chromatogr. B. 907 (2012) 101-107; DOI: 10.1016/j.jchromb.2012.09.009.

  • 24. H. Kirchherr and W. N. Kühn-Velten Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: A multi-level singlesample approach J. Chromatogr. B. 843 (2006) 100-113.

  • 25. K. K. Erickson-Ridout D. Sun and P. Lazarus Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms Pharmacogen. Gen. 22 (2012) 561-576; DOI: 10.1097/FPC.0b013e328354026b.

  • 26. J. Leon Glucuronidation enzymes genes and psychiatry Int. J. Neuropsychoph. 6 (2003) 57-72.

  • 27. H. L. Liston J. S. Markowitz and C. L. de Vane Drug glucuronidation in clinical psychopharmacology J. Clin. Psychopharmacol. 21 (2001) 500-515.

  • 28. A. Y. Khan and S. H. Preskorn Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring J. Psychiatr. Pract. 11 (2005) 289-301.

  • 29. E. Spina A. Avenoso G. Facciolà M.G. Scordo M Ancione A. G. Madia A. Ventimiglia and E. Perucca Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics Psychopharmacology 148 (2000) 83-89.

  • 30. P. J. Perry D. D. Miller S. V. Arndt and R. J. Cadoret Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients Am. J. Psychiatry 148 (1991) 231-235.

  • 31. O. V. Olesen K. Thomsen P. N. Jensen C. Wulff N. A. Rasmussen C. Refshammer J. Sørensen M. Bysted J. Christensen and R. Rosenberg Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study Psychopharmacology 117 (1995) 371-378.

  • 32. D. J. Freeman and L. K. Oyewumi Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin. Pharmacokinet. 32 (1997) 93-100.

  • 33. S. K. Lin S. F. Su and C. Pan Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms Ther. Drug Monit. 28 (2006) 303-307.

  • 34. M. van der Molen-Eijgenraam J. T. Blanken-Meijs M. Heeringa and A. C. van Grootheest Delirium due to increase in clozapine level during an inflammatory reaction Ned. Tijdschr. Geneeskd. 145 (2001) 427-430.

  • 35. J. A. Carrillo A. G. Herraiz S. I. Ramos and J. Benítez Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients J. Clin. Psychopharmacol. 18 (1998) 311-316.

  • 36. V. Ozdemir W. Kalow P. Posner E. J. Collins J. L. Kennedy B. K. Tang L. J. Albers C. Reist R. Roy W. Walkes and P. Afra CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia J. Clin. Psychopharmacol. 21 (2001) 398-407.

  • 37. C. Hiemke P. Baumann N. Bergemann A. Conca O. Dietmaier K. Egberts M. Fric M. Gerlach C. Greiner G. Gründer E. Haen U. Havemann-Reinecke E. Jaquenoud Sirot H. Kirchherr G. Laux U. C. Lutz T. Messer M. J. Müller B. Pfuhlmann B. Rambeck P. Riederer B. Schoppek J. Stingl M. Uhr S. Ulrich R. Waschgler and G. Zernig AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 Pharmacopsychiatry 44 (2011) 195-235; DOI: 10.1055/s-0031-1286287.

  • 38. E. Ceskova Would therapeutic drug monitoring improve adherence and efficaccy of treatment in schizophrenia? Psychiat. Prax. 12 (2011) 166-178.

  • 39. K. Seto J. Dumontet and M. H. Ensom Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther. Drug Monit. 33 (2011) 275-283; DOI: 10.1097/FTD.0b013e3182126d83.

  • 40. E. Spina A. Avenoso G. Facciolà M. Salemi M. G. Scordo M. Ancione A. G. Madia and E. Perucca Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia Psychopharmacology 153 (2001) 238-243.

  • 41. J. K. Darby D. J. Pasta M. G. Wilson and J. Herbert Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical twogroup naturalistic study Clin. Drug Invest. 28 (2008) 553-564.

  • 42. L. Citrome Oral paliperidone extended-release: chemistry pharmacodynamics pharmacokinetics and metabolism clinical efficacy safety and tolerability Expert Opin. Drug Metab. Toxicol. 8 (2012) 873-888; DOI: 10.1517/17425255.2012.693160.

  • 43. P. G. Janicak and E. A. Winans Paliperidone ER: a review of the clinical trial data Neuropsychiatr. Dis. Treat. 3 (2007) 869-897.

  • 44. K. K. Erickson-Ridout J. Zhu and P. Lazarus Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants Pharmacogenet. Genomics 21 (2011) 539-551; DOI: 10.1097/ FPC.0b013e328348c76b.

  • 45. G. Gründer C. Hiemke M. Paulzen T. Veselinovic and I. Vernaleken Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging Pharmacopsychiatry 44 (2011) 236-248; DOI: 10.1055/s-0031-1286282.

  • 46. O. Gefvert M. Bergström B. Långström T. Lundberg L. Lindström and R. Yates Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentration after discontinuation of quetiapine (Seroquet) in patients with schizophrenia Psychopharmacology 135 (1998) 119-126.

  • 47. M. C. Mauri A. Fiorentini and L. S. Volonteri Quetiapine in acute psychosis and personality disorders during hospitalization: assessment of a therapeutic range Eur. Neuropsychopharmacol. 14 (2004) 283-284.

  • 48. J. R. Fabre L. Arvanitis J. Pultz V. M. Jones J. B. Malick and V. B. Slotnick ICI 204.636. a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia Clin. Ther. 17 (1995) 366-378.

  • 49. J. G. Small S. R. M. Hirsch L. A. Arvanitis B. G. Miller and C. G. Link Quetiapine in patients with schizophrenia: a high- and low-dose double blind comparison with placebo Arch. Gen. Psych. 54 (1997) 549-557.

  • 50. A. Sparshatt D. Taylor M. X. Patel and S. Kapur Amisulpride - dose plasma concentration occupancy and response: implications for therapeutic drug monitoring Acta Psychiatr. Scand. 120 (2009) 416-428; DOI: 10.1111/j.1600-0447.2009.01429.x.

  • 51. M. J. Müller B. Regenbogen S. Härtter F. X. Eich and C. Hiemke Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia J. Psychiatr. Res. 41 (2007) 673-679.

  • 52. F. Vogel R. Gansmüller T. Leiblein O. Dietmaier H. Wassmuth G. Gründer and C. Hiemke The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey Eur. Psychiatry 24 (2009) 143-148; DOI: 10.1016/j. eurpsy.2008.09.003.

  • 53. M. D. Cherma M. Reis S. Hägg J. Ahlner and F. Bengtsson Therapeutic drug monitoring of ziprasidone in a clinical treatment setting Ther. Drug Monit. 30 (2008) 682-688; DOI: 10.1097/ FTD.0b013e31818ac8ba.

  • 54. A. Sparshatt D. Taylor M. X. Patel and S. Kapur A systematic review of aripiprazole-dose plasma concentration receptor occupancy and response: implications for therapeutic drug monitoring J. Clin. Psychiatry 71 (2010) 1447-1456; DOI: 10.4088/JCP.09r05060gre.

Journal information
Impact Factor

IMPACT FACTOR 2018: 1,405
5-year IMPACT FACTOR: 1,701

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.314
Source Normalized Impact per Paper (SNIP) 2018: 0.637

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 734 528 23
PDF Downloads 329 262 7